HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report

Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion should be read in conjunction with the Huifend Bio-Pharmaceutical Techonology, Inc. consolidated financial statements and accompanying notes included elsewhere in this report. The following discussion contains forward-looking statements that reflect the plans, estimates and beliefs of Huifeng Bio-Pharmaceutical Technology, Inc. The actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Report and the Annual Report 10-K, particularly in "Risk Factors" section in the Annual Report on 10-K. All references to years relate to the calendar year ended December 31 of the particular year. OVERVIEW History On December 20, 2004, pursuant to the Malone Agreement, Art Malone, Jr. sold 7,229,601 shares of the common stock of the Company, or 56% of the Company's outstanding common stock, for $300,000 (the "Sale") to Zhi Lan Wang and Jun Lin on December 20, 2004. Immediately thereafter, on December 20, 2004 the Company completed a Northwest Agreement, pursuant to which the Company initially purchased 30% of the common shares of Northwest BioTechnic, Inc. ("NBTI") in exchange for 80,735,590 shares of the Company's common stock ("Acquisition"). The purchase price for the remaining 70% of NBTI's common shares was $1,900,000 payable by the Company's issuance of a promissory note ("Promissory Note") on December 20, 2004. The Promissory Note was subsequently converted into 10,465,725 (post a one for eighteen reverse split) shares of the Company's common stock. At the closing of the transaction, 80,735,590 shares of the common stock of the Company sold represented approximately 86.3% of the total outstanding stock of the Company. NBTI was incorporated in...
Click here to read the whole Article (external link)

HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers

Show all filings for HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC. 10-Nov-2009Change in Directors or Principal Officers Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All informatio...
Click here to read the whole Article (external link)

Opportunities in Cheap China Stocks

Stock quotes in this article: SGAS.OB , CHME.OB , LTUS.OB , ...
Click here to read the whole Article (external link)

HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC. Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)

HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities

Show all filings for HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC. 2-Sep-2009Unregistered Sale of Equity Securities Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information pr...
Click here to read the whole Article (external link)

HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report

Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion should be read in conjunction with the Huifend Bio-Pharmaceutical Techonology, Inc. consolidated financial statements and accompanying notes included elsewhere in this report. The following discussion contains forward-looking statements that reflect the plans, estimates and beliefs of Huifeng Bio-Pharmaceutical Technology, Inc. The actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Report and the Annual Report 10-K, particularly in "Risk Factors" section in the Annual Report on 10-K. All references to years relate to the calendar year ended December 31 of the particular year. OVERVIEW History On December 20, 2004, pursuant to the Malone Agreement, Art Malone, Jr. sold 7,229,601 shares of the common stock of the Company, or 56% of the Company's outstanding common stock, for $300,000 (the "Sale") to Zhi Lan Wang and Jun Lin on December 20, 2004. Immediately thereafter, on December 20, 2004 the Company completed a Northwest Agreement, pursuant to which the Company initially purchased 30% of the common shares of Northwest BioTechnic, Inc. ("NBTI") in exchange for 80,735,590 shares of the Company's common stock ("Acquisition"). The purchase price for the remaining 70% of NBTI's common shares was $1,900,000 payable by the Company's issuance of a promissory note ("Promissory Note") on December 20, 2004. The Promissory Note was subsequently converted into 10,465,725 (post a one for eighteen reverse split) shares of the Company's common stock. The 80,735,590 shares of the common stock of the Company sold represented approximately 86.3% of the total outstanding stock of the Company. NBTI was incorporated in the British Virgin Islands on J...
Click here to read the whole Article (external link)

HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report

Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion should be read in conjunction with the Huifend Bio-Pharmaceutical Techonology, Inc. consolidated financial statements and accompanying notes included elsewhere in this report. The following discussion contains forward-looking statements that reflect the plans, estimates and beliefs of Huifeng Bio-Pharmaceutical Technology, Inc. The actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Report and the Annual Report 10-K, particularly in "Risk Factors." All references to years relate to the calendar year ended December 31 of the particular year. OVERVIEW The audited consolidated financial statements include the accounts of Huifeng Bio-Pharmaceutical, Inc., a Nevada corporation, and its subsidiaries. We are in the business of producing and selling plant extracts, biochemical products and pharmaceutical raw products in the PRC. On December 20, 2004, pursuant to a Stock Purchase Agreement, Art Malone, Jr. ("Selling Shareholder") sold 7,229,601 shares of the common stock of the Company for $300,000 (the "Sale") to Zhi Lan Wang and Jun Lin, individuals on the closing date of December 20, 2004. Such 7,229,601 shares of the common stock of the Company represented approximately 56.18% of the total outstanding stock of the Company as of that date. Immediately thereafter, pursuant to the terms of an Agreement and Plan of Reorganization dated December 20, 2004 ("Northwest Agreement"), the Company agreed to purchase all of the outstanding shares of Northwest BioTechnic, Inc. ("NBTI"), a British Virgin Islands corporation (the "Acquisition"). NBTI was incorporated in the British Virgin Islands on June 25, 2004. At the time of the Acquisition,...
Click here to read the whole Article (external link)

HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC. Files SEC form 10-K, Annual Report

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION Cautionary Statement This annual report contains forward-looking statements within the meaning of the federal securities laws. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as "anticipate," "expect," "intend," "plan," "will," "we believe," "HFGB believes," "management believes" and similar language. The forward-looking statements are based on the current expectations of HFGB and are subject to certain risks, uncertainties and assumptions, including those set forth in the discussion under "Description of Business" and "Management's Discussion and Analysis of Financial Condition and Results of Operation." The actual results may differ materially from results anticipated in these forward-looking statements. We base the forward-looking statements on information currently available to us, and we assume no obligation to update them. History On December 20, 2004, pursuant to the Malone Agreement, Art Malone, Jr. ("Selling Shareholder") sold 7,229,601 shares of the common stock of the Company for $300,000 (the "Sale") to Zhi Lan Wang and Jun Lin, individuals on the closing date of December 20, 2004. As a result, the 7,229,601 shares of the common stock of the Company sold represented approximately 56.18% of the total outstanding stock of the Company. Immediately thereafter, On December 20, 2004 HFGB completed a Northwest Agreement, of which the Company initially purchased 30% of the common shares of NBTI in exchange for 80,735,590 shares of the Company's common stock ("Acquisition"). The purchase price for the remaining 70% of NBTI's common shares was $1,900,000 payable by the Company's issuance of a promissory note ("Promissory Note&q...
Click here to read the whole Article (external link)

HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report

Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion should be read in conjunction with the Huifend Bio-Pharmaceutical Techonology, Inc. consolidated financial statements and accompanying notes included elsewhere in this report. The following discussion contains forward-looking statements that reflect the plans, estimates and beliefs of Huifeng Bio-Pharmaceutical Technology, Inc. The actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Report and the Annual Report 10-K, particularly in "Risk Factors." All references to years relate to the calendar year ended December 31 of the particular year. OVERVIEW The audited consolidated financial statements include the accounts of Huifeng Bio-Pharmaceutical, Inc., a Nevada corporation, and its subsidiaries. We are in the business of producing and selling plant extracts, biochemical products and pharmaceutical raw products in the PRC. On December 20, 2004, pursuant to a Stock Purchase Agreement, Art Malone, Jr. ("Selling Shareholder") sold 7,229,601 shares of the common stock of the Company for $300,000 (the "Sale") to Zhi Lan Wang and Jun Lin, individuals on the closing date of December 20, 2004. Such 7,229,601 shares of the common stock of the Company represented approximately 56.18% of the total outstanding stock of the Company as of that date. Immediately thereafter, pursuant to the terms of an Agreement and Plan of Reorganization dated December 20, 2004 ("Northwest Agreement"), the Company agreed to purchase all of the outstanding shares of Northwest BioTechnic, Inc. ("NBTI"), a British Virgin Islands corporation (the "Acquisition"). NBTI was incorporated in the British Virgin Islands on June 25, 2004. At the time of the Acquisition,...
Click here to read the whole Article (external link)